Oxford, UK-based precision health company developing medical imaging tools, Perspectum, raised USD 36 million in the first close of Series C financing. The company announced the closure on January 5, 2023. Oppenheimer Holdings led the financing for the firm. So far, the total capital raised by the firm stands at approximately USD 120 million.
Purpose of funding for Perspectum
With the latest financing from Series C financing, Perspectum intends to scale up its US operations. Meanwhile, the company has plans to deploy funds towards accelerating its product pipeline for multiorgan inflammatory conditions and oncology.
Earlier in December 2022, Perspectum announced a collaboration with a Microsoft company called Nuance.
What the company’s official has to say
Rajarshi Banerjee, MD, PhD, CEO of Perspectum, said, “We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies that will help clinicians shorten patients’ diagnostic and treatment journeys. This new funding will help us to continue innovating new products. It will make healthcare safer by providing non-invasive alternatives to biopsy, totally changing how and when we can see and treat many diseases.”
What the investor has to say
Robert Lowenthal, President of Oppenheimer Holdings, further added, “Perspectum is a truly disruptive company with medical imaging software that can dramatically improve the standard of care for millions of patients, as well as provide a higher level of decision support for physicians. We anticipate Perspectum will continue to lead the field of AI-enhanced imaging for years to come.”
What the British Patient Official has to say
Catherine Lewis La Torre, CEO of British Patient Capital, said, “Life sciences and deep tech are two bright spots within the UK’s innovation economy, and Perspectum is bringing the two together as they pioneer technological developments that are revolutionizing the patient experience. Through our Future Fund: Breakthrough programme, we are excited to work with an industry-leading team at Perspectum and support their global growth ambitions.”
About the company
In 2012, Founders Matthew Robson, Michael Brady, Rajarshi Banerjee, and Stefan Neubauer launched the company. The company is a global medical technology company with offices in the US, the UK, Portugal, and Singapore. It delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multiorgan pathology, and cancer. Its vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment leveraging advanced imaging and genetic
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
